anti-CEA CAR-T cells + nanoliposomal irinotecan + fluorouracil + folinic acid

This is an **experimental multi-agent regimen** combining anti-CEA chimeric antigen receptor T cells (CAR-T cells) with nanoliposomal irinotecan, fluorouracil (5-FU), and folinic acid (leucovorin), primarily investigated for treating **CEA-expressing solid tumors** such as metastatic pancreatic adenocarcinoma and colorectal cancers. - **Anti-CEA CAR-T cells** are autologous T lymphocytes genetically modified to express a CAR targeting carcinoembryonic antigen (CEA), enabling direct recognition and killing of CEA-positive tumor cells and reprogramming the tumor microenvironment for heightened anti-tumor immunity[1][3][5]. - **Nanoliposomal irinotecan** is a liposome-formulated topoisomerase I inhibitor that enables enhanced tumor delivery and sustained drug activity, inducing DNA damage and apoptosis[4]. - **Fluorouracil** is a pyrimidine analog that inhibits thymidylate synthase, thus interfering with DNA synthesis[4][6]. - **Folinic acid** enhances the binding of fluorouracil to thymidylate synthase, increasing its cytotoxicity[4][6]. This combination aims to leverage **CAR-T cell immunotherapy** with conventional chemotherapeutics, potentially overcoming resistance and improving outcomes in solid tumors that are otherwise difficult to treat. Clinical data are emerging but indicate encouraging biologic activity, particularly in cases resistant to conventional systemic therapy[5].